Protective effects of booster dose of SARS-COV-2 vaccination against post-acute COVID-19 syndrome: A systematic review
- 19 June 2025
- journal article
- review article
- Published by SAGE Publications in Journal of Investigative Medicine
- Vol. 73 (8) , 606-613
Abstract
The global impact of COVID-19, caused by SARS-CoV-2, has extended beyond acute infection, with post-acute COVID-19 syndrome (PACS) affecting an estimated 10% of recovered individuals. PACS manifests a range of debilitating symptoms, including fatigue, cognitive impairment, and gastrointestinal issues. While vaccination has proven effective in mitigating severe COVID-19 outcomes, the role of booster doses in preventing PACS remains unclear. This study aimed to evaluate whether COVID-19 booster vaccinations reduce the incidence and severity of PACS in individuals with prior SARS-CoV-2 infection. A systematic review and meta-analysis were conducted, adhering to Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. Databases PubMed, Embase, and Cochrane were searched for peer-reviewed studies published in English from January 2020 to August 2023. Inclusion criteria encompassed randomized controlled trials, prospective cohort studies, and case-control studies comparing PACS prevalence between booster recipients and non-recipients. The risk of bias was assessed using the Joanna Briggs Institute appraisal tool. Data synthesis included pooled prevalence estimates and narrative analyses. Of 849 identified studies, 22 met inclusion criteria, with 12 providing complete data for meta-analysis. Among 38,718 participants, a trend toward lower PACS prevalence was observed in booster recipients (RR: 0.66; 95% CI: 0.41–1.09), though heterogeneity (I 2 = 98%) limited statistical significance. Risk of bias analysis classified most studies as low or moderate risk, with two high-risk studies reporting higher PACS rates in boosted individuals. This study suggests a potential protective effect of booster vaccinations against PACS, though findings were not statistically significant. Further research with larger, standardized cohorts is essential to validate these observations and guide vaccination strategies. Prospero Record Number: CRD42023461326Keywords
This publication has 27 references indexed in Scilit:
- Persistence in risk and effect of COVID-19 vaccination on long-term health consequences after SARS-CoV-2 infectionNature Communications, 2024
- A Cross-Sectional Study of Symptom Prevalence, Frequency, Severity, and Impact of Long COVID in Scotland: Part IThe American Journal of Medicine, 2023
- Prevalence and risk factors of long COVID 6–12 months after infection with the Omicron variant among nonhospitalized patients in Hong KongJournal of Medical Virology, 2023
- Development of a Definition of Postacute Sequelae of SARS-CoV-2 InfectionJAMA, 2023
- Self-reported long COVID-19 symptoms are rare among vaccinated healthcare workersJournal of Infection and Public Health, 2023
- Risk factors for long coronavirus disease 2019 (long COVID) among healthcare personnel, Brazil, 2020–2022Infection Control & Hospital Epidemiology, 2023
- Protective effect of COVID-19 vaccination against long COVID syndrome: A systematic review and meta-analysisVaccine, 2023
- Outcomes among confirmed cases and a matched comparison group in the Long-COVID in Scotland studyNature Communications, 2022
- Impact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms: A systematic revieweClinicalMedicine, 2022
- Association Between BNT162b2 Vaccination and Long COVID After Infections Not Requiring Hospitalization in Health Care WorkersJAMA, 2022